The childhood asthma management program (CAMP): Design, rationale, and methods

Childhood Asthma Management Program Research Group

doi:10.1016/S0197-2456(98)00044-0

The childhood asthma management program (CAMP): Design, rationale, and methods

Childhood Asthma Management Program Research Group

Research output: Contribution to journal › Article › peer-review

325 Scopus citations

Abstract

The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting β-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol. One thousand forty-one children (32% from ethnic minority groups), aged 5 to 12 years at screening, are currently participating. The primary outcome measure is lung growth as indicated by postbronchodilator forced expiratory volume in 1 second (FEV₁) percent of predicted, observed over 5- to 6-year period. The trial also assesses differences between treatment groups with respect to airway responsiveness, morbidity, physical growth and development, and psychological growth and development. This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial.

Original language	English (US)
Pages (from-to)	91-120
Number of pages	30
Journal	Controlled Clinical Trials
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/S0197-2456(98)00044-0
State	Published - Feb 1999
Externally published	Yes

Funding

The Childhood Asthma Management Program is supported by Contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute. Appendix The members of the CAMP Research Group as of February 1998 are as follows.

Keywords

Albuterol
Allergens
Anti-inflammatory agents
Atopy
Bronchial provocation test
Bronchodilator agents
Budesonide
Childhood asthma
Clinical trials
Environmental exposure
Glucocorticoids
Growth
Inhaled bronchodilator
Nedocromil
Psychological test
Spirometry

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0197-2456(98)00044-0

Cite this

@article{dad10278440c4d13ae4dee7ef11208da,

title = "The childhood asthma management program (CAMP): Design, rationale, and methods",

abstract = "The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting β-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol. One thousand forty-one children (32% from ethnic minority groups), aged 5 to 12 years at screening, are currently participating. The primary outcome measure is lung growth as indicated by postbronchodilator forced expiratory volume in 1 second (FEV1) percent of predicted, observed over 5- to 6-year period. The trial also assesses differences between treatment groups with respect to airway responsiveness, morbidity, physical growth and development, and psychological growth and development. This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial.",

keywords = "Albuterol, Allergens, Anti-inflammatory agents, Atopy, Bronchial provocation test, Bronchodilator agents, Budesonide, Childhood asthma, Clinical trials, Environmental exposure, Glucocorticoids, Growth, Inhaled bronchodilator, Nedocromil, Psychological test, Spirometry",

author = "{Childhood Asthma Management Program Research Group} and Shapiro, {Gail G.} and DuHamel, {Thomas R.} and Wighton, {Timothy G.} and Tamara Chinn and Bierman, {C. Warren} and Furukawa, {Clifton T.} and Altman, {Leonard C.} and Virant, {Frank S.} and Williams, {Paul V.} and Minotti, {Dominick A.} and Kennedy, {Michael S.} and Becker, {Jonathan W.} and Chris Reagan and Heather Eliassen and Dan Crawford and Babi Hammond and Grace Strodtbeck and Marian Sharpe and Scott Weiss and Dirk Greineder and Walter Torda and Martha Tata and Peter Barrant and Anthony DeFilippo and Mary Grace and Stephanie Haynes and Margaret Higham and Susan Kelleher and Jay Koslof and Nancy Madden and Dana Mandel and Agnes Martinez and Jean McAuliffe and Paola Pacella and Paula Parks and Anne Plunkett and Kay Seligsohn and June Traylor and {Van Horn}, Melissa and Janice Ware and Carolyn Wells and Ann Whitman and Joe Reisman and Ian MacLusky and Henry Levison and Anita Hall and Yola Benedet and Jennifer Chay and Michelle Collinson and Sai Nimmagadda",

note = "Publisher Copyright: {\textcopyright} Elsevier Science Inc. 1999.",

year = "1999",

month = feb,

doi = "10.1016/S0197-2456(98)00044-0",

language = "English (US)",

volume = "20",

pages = "91--120",

journal = "Controlled Clinical Trials",

issn = "0197-2456",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - The childhood asthma management program (CAMP)

T2 - Design, rationale, and methods

AU - Childhood Asthma Management Program Research Group

AU - Shapiro, Gail G.

AU - DuHamel, Thomas R.

AU - Wighton, Timothy G.

AU - Chinn, Tamara

AU - Bierman, C. Warren

AU - Furukawa, Clifton T.

AU - Altman, Leonard C.

AU - Virant, Frank S.

AU - Williams, Paul V.

AU - Minotti, Dominick A.

AU - Kennedy, Michael S.

AU - Becker, Jonathan W.

AU - Reagan, Chris

AU - Eliassen, Heather

AU - Crawford, Dan

AU - Hammond, Babi

AU - Strodtbeck, Grace

AU - Sharpe, Marian

AU - Weiss, Scott

AU - Greineder, Dirk

AU - Torda, Walter

AU - Tata, Martha

AU - Barrant, Peter

AU - DeFilippo, Anthony

AU - Grace, Mary

AU - Haynes, Stephanie

AU - Higham, Margaret

AU - Kelleher, Susan

AU - Koslof, Jay

AU - Madden, Nancy

AU - Mandel, Dana

AU - Martinez, Agnes

AU - McAuliffe, Jean

AU - Pacella, Paola

AU - Parks, Paula

AU - Plunkett, Anne

AU - Seligsohn, Kay

AU - Traylor, June

AU - Van Horn, Melissa

AU - Ware, Janice

AU - Wells, Carolyn

AU - Whitman, Ann

AU - Reisman, Joe

AU - MacLusky, Ian

AU - Levison, Henry

AU - Hall, Anita

AU - Benedet, Yola

AU - Chay, Jennifer

AU - Collinson, Michelle

AU - Nimmagadda, Sai

PY - 1999/2

Y1 - 1999/2

N2 - The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting β-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol. One thousand forty-one children (32% from ethnic minority groups), aged 5 to 12 years at screening, are currently participating. The primary outcome measure is lung growth as indicated by postbronchodilator forced expiratory volume in 1 second (FEV1) percent of predicted, observed over 5- to 6-year period. The trial also assesses differences between treatment groups with respect to airway responsiveness, morbidity, physical growth and development, and psychological growth and development. This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial.

AB - The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting β-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol. One thousand forty-one children (32% from ethnic minority groups), aged 5 to 12 years at screening, are currently participating. The primary outcome measure is lung growth as indicated by postbronchodilator forced expiratory volume in 1 second (FEV1) percent of predicted, observed over 5- to 6-year period. The trial also assesses differences between treatment groups with respect to airway responsiveness, morbidity, physical growth and development, and psychological growth and development. This report describes the design of the trial, the rationale for the design choices made, and the methods used to carry out the trial.

KW - Albuterol

KW - Allergens

KW - Anti-inflammatory agents

KW - Atopy

KW - Bronchial provocation test

KW - Bronchodilator agents

KW - Budesonide

KW - Childhood asthma

KW - Clinical trials

KW - Environmental exposure

KW - Glucocorticoids

KW - Growth

KW - Inhaled bronchodilator

KW - Nedocromil

KW - Psychological test

KW - Spirometry

UR - http://www.scopus.com/inward/record.url?scp=0033012176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033012176&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(98)00044-0

DO - 10.1016/S0197-2456(98)00044-0

M3 - Article

C2 - 10027502

AN - SCOPUS:0033012176

SN - 0197-2456

VL - 20

SP - 91

EP - 120

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

IS - 1

ER -

The childhood asthma management program (CAMP): Design, rationale, and methods

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this